Michael L. Babich

Former Director, President & Chief Executive Officer at INSYS Therapeutics, Inc.

Michael L. Babich

Michael L. Babich

Former Director, President & Chief Executive Officer at INSYS Therapeutics, Inc.

Overview
Career Highlights

InSys Therapeutics, Inc. (Inactive)
INSYS Therapeutics, Inc.

RelSci Relationships

97

Number of Boards

4

Birthday

1977

Age

44

Relationships
RelSci Relationships are individuals Michael L. Babich likely has professional access to. A relationship does not necessarily indicate a personal connection.

President at EJ Financial Enterprises, Inc.

Relationship likelihood: Strong

Former Chief Executive Officer & Executive Vice President at Rhone-Poulenc Rorer, Inc.

Relationship likelihood: Strong

Chief Financial Officer at JVM Capital LLC

Relationship likelihood: Strong

Fund Advisor at EJF Capital LLC

Relationship likelihood: Strong

President, Chief Executive Officer & Director at New Haven Pharmaceuticals, Inc.

Relationship likelihood: Strong

Founder at Third Age Pharma LLC

Relationship likelihood: Strong

Chairman, President & Chief Executive Officer at UbiVac LLC

Relationship likelihood: Strong

Former Professional at Abbott Laboratories

Relationship likelihood: Strong

Partner at Southport Marina Development Co. LLC

Relationship likelihood: Strong

Chief Scientific Officer at INSYS Therapeutics, Inc.

Relationship likelihood: Strong

Paths to Michael L. Babich
Potential Connections via
Relationship Science
You
Michael L. Babich
Former Director, President & Chief Executive Officer at INSYS Therapeutics, Inc.
Career History
Chief Operating Officer & Director
2007 - 2011

InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ.

Director, President & Chief Executive Officer
2007 - 2015

INSYS Therapeutics, Inc. operates as a pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products that include Subsys, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients; and Syndros, a proprietary orally administered liquid formulation of dronabinol for the treatment of CINV and anorexia associated with weight loss in patients with AIDS. The company was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ.

Boards & Committees
President, Chief Executive Officer, Director
2010 - 2015
Chief Operating Officer & Director
2007 - 2011
Director
2006 - 2006
Transactions
Details Hidden

INSYS Therapeutics, Inc. raised money in a private placement transaction

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Michael L. Babich. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Michael L. Babich's profile does not indicate a business or promotional relationship of any kind between RelSci and Michael L. Babich.